Comparative Pharmacology
Head-to-head clinical analysis: FERNISOLONE P versus HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERNISOLONE P versus HYDROCORTISONE.
FERNISOLONE-P vs HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FERNISOLONE-P is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators like prostaglandins and leukotrienes.
Hydrocortisone is a glucocorticoid that binds to the glucocorticoid receptor (GR), leading to altered gene expression. This results in anti-inflammatory, immunosuppressive, anti-proliferative, and vasoconstrictive effects. It also modulates carbohydrate, protein, and lipid metabolism.
5-60 mg orally once daily or in divided doses; intravenous, intramuscular, or intra-articular administration per specific indication.
Oral: 10-20 mg every 6-8 hours; IV/IM: 100-500 mg every 2-6 hours for acute conditions; typical maintenance: 20-240 mg/day divided every 8-12 hours.
None Documented
None Documented
Clinical Note
moderateHydrocortisone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gatifloxacin."
Clinical Note
moderateHydrocortisone + Rosoxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rosoxacin."
Clinical Note
moderateHydrocortisone + Levofloxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Levofloxacin."
Clinical Note
moderate3.5 hours; in renal impairment (CrCl <30 mL/min) may extend to 8-10 hours, requiring dose adjustment
Terminal half-life: 1.5–2 hours (plasma). In tissues, biologic half-life is 8–12 hours due to intracellular activity. Half-life prolonged in hepatic impairment.
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% other
Renal: primarily as inactive metabolites (cortisone, tetrahydrocortisone) and unchanged drug (<1%). Biliary/fecal: minimal (<5%).
Category C
Category D/X
Corticosteroid
Corticosteroid
Hydrocortisone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trovafloxacin."